Diabetes Metab Syndr Obes. 2014 Jul 29;7:347-55. doi: 10.2147/DMSO.S46674. eCollection 2014.
Diabetes, metabolic syndrome and obesity : targets and therapy
Jocelyn S Garland
PMID: 25114577 PMCID: PMC4122576 DOI: 10.2147/DMSO.S46674
Chronic kidney disease (CKD) is defined by the National Kidney Foundation Kidney Disease Outcomes Quality Initiative as the presence of reduced kidney function or kidney damage for a period of 3 months or greater. Obesity is considered a risk factor for CKD development, but its precise role in contributing to CKD and end stage kidney disease is not fully elucidated. In this narrative review, the objectives are to describe the pathogenesis of CKD in obesity, including the impact of altered adipokine secretion in obesity and CKD, and to provide an overview of the clinical studies assessing the risk of obesity and CKD development.
Keywords: adipokine; chronic renal disease; obesity